BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET

About this update from Biomarin Pharmaceutical Inc.

SAN RAFAEL, Calif. , April 17, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy , President and Chief Executive Officer of BioMarin , will host a conference call and webcast on Thursday, May 1, 2025 , at 4:30 p.m. ET to discuss first quarter 2025 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial -in Number: 888-596-4144International Dial-in Number: 646-968-2525Conference Call ID: 4327591 U.S. / Canada Replay Dial -in Number: 800-770-2030 International Replay Dial -in Number: 609-800-9909Playback ID: 4327591 Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/ . A replay of the call will be archived on the site for one week following the call. About BioMarin BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California -based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin pursues treatments that offer new possibilities for patients and families around the world navigating rare or difficult-to-treat genetic conditions. To learn more, please visit www.biomarin.com . Contacts: Investors Media Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 View original content to download multimedia: https://www.prnewswire.com/news-releases/biomarin-to-host-first-quarter-2025-financial-results-conference-call-and-webcast-on-thursday-may-1-2025-at-430pm-et-302430811.html SOURCE BioMarin Pharmaceutical Inc.

View stock analysis, news, and events for Biomarin Pharmaceutical Inc.